A small molecule, not a peptide, that blocks an enzyme called NNMT. The mouse data are consistent and interesting. There are no human trials at all.
5-Amino-1MQ shows up in the same online catalogs as the peptides, and it gets discussed the same way, but it isn't one. It's a small synthetic molecule, and the distinction matters more than it sounds. What it does is block an enzyme called NNMT, which quietly drains two things your cells need: the raw material for NAD+, and the cell's main methyl donor. Turn that enzyme down in a mouse and the mouse loses fat without eating less. That result is real, it's been reproduced, and the mechanism behind it is genuinely elegant. Here's the part the sales pages leave out. Not one human being has been studied in a published clinical trial. Not for safety, not for effectiveness, not at any dose, by any route. Everything anyone knows about this compound in people is guesswork scaled down from mice.
5-amino-1-methylquinolinium, sometimes shortened to 5A1MQ. It's a quinolinium-class molecule weighing about 159 grams per mole, which is tiny compared to the peptides it's sold alongside. Peptides are short chains of amino acids. This is a two-ring aromatic structure with an amino group and a methyl group attached. Because it's small and membrane-permeable, it can cross into cells and reach an enzyme that sits inside them, which is something most peptides can't do. It came out of academic drug-discovery work at the University of Texas. Calling it a peptide isn't a harmless shorthand. It signals that whoever wrote the page didn't check.
The biological context for 5-Amino-1MQ sits at the intersection of adipose tissue and fat metabolism, NAD+ metabolism, and skeletal muscle. The thread connecting them is a single enzyme, NNMT, whose activity affects how cells manage their NAD+ precursors and methyl groups. Read this as a systems-level orientation to why the target is interesting, not as evidence that inhibiting it changes body composition or muscle function in a person. Mechanism, animal data, and human evidence belong in separate lanes, and on this page the human lane is empty.
NNMT, nicotinamide N-methyltransferase, takes nicotinamide (a form of vitamin B3 and a building block for NAD+) and attaches a methyl group to it, using SAM, the cell's universal methyl donor. Both ingredients get consumed. In healthy young tissue, NNMT activity is low and nothing's wrong. In obese fat tissue, NNMT is overexpressed, so it's constantly siphoning off NAD+ precursor and methyl groups. 5-Amino-1MQ binds the enzyme's active site and slows it down, which in cell culture raises NAD+ and SAM and suppresses fat storage. It's selective, meaning it hits NNMT without knocking out the related methyltransferases. That's the mechanism, and it's a good one. But a good mechanism is a hypothesis about what will happen in a person, not a demonstration.
Human data. The reviewed sources do not include direct human studies, because none exist: there are no published human trials of 5-Amino-1MQ of any kind, for safety or for effectiveness. Everything claimed about its effects in people is extrapolated from rodent and cell work. Human-facing conclusions - about fat loss, safety, or anything else - should therefore be treated as unestablished rather than likely.
Preclinical data. The evidence is a tidy stack of rodent and cell studies. The foundational paper (Kraus, Nature, 2014) showed that shutting NNMT down genetically protects mice from diet-induced obesity, which is what made NNMT a target worth chasing. Read that sentence carefully, because it's the one most often misused: that study did not test 5-Amino-1MQ. It used genetic knockdown, years before the molecule existed. The paper that actually tested the compound (Neelakantan, 2018) gave it to diet-induced obese mice for eleven days and saw reduced body weight, less white fat, and smaller fat cells, with no change in how much the mice ate. A follow-up (2019) found that the same class of inhibitor improved muscle regeneration and strength in aged mice, opening a second research direction. And then there's the study that complicates things. When researchers deleted NNMT genetically (Brachs, 2019), the results were messier: males on a high-fat diet got better insulin sensitivity, females on a Western diet lost fat, and glucose tolerance didn't improve. The effect depended on sex and on diet. That's what real biology looks like, and it's more honest than a clean story. There are zero human trials.
Anecdotal discussion. Online, 5-Amino-1MQ is sold and discussed as a fat-loss aid, often mislabeled as a peptide and often citing the wrong study (the 2014 genetic-knockdown paper, which never tested the molecule). Reports of what "users experience" over a course of weeks are anecdote, uncontrolled, unblinded, and impossible to separate from diet, training, or expectation. Anecdote can explain why the compound is visible; it cannot establish that it works or that it is safe.
The limitations here are unusually stark: there is no human data at all, so every human-facing question - does it work, is it safe, at what exposure - is unanswered. Even within the animal literature the picture is not clean. When researchers deleted the enzyme genetically, the results were sex- and diet-specific, and glucose tolerance did not improve; real biology rarely gives a tidy story. And the single most-cited "proof", the 2014 Nature paper, tested genetic knockdown, not the molecule itself. Preclinical consistency is a reason to keep watching, not a reason to conclude.
There is no human safety data. That isn't a warning about a known risk; it's the absence of information. No published trial has established a safe exposure in people, no dose-limiting toxicity has been identified, and no adverse-event dataset exists. The mouse studies reported no obvious problems in short treatment windows, which tells you something about mice over days, not about people over months. Reputable suppliers label this material for laboratory research and state that it isn't for human consumption. Nothing on this page is medical advice.
5-Amino-1MQ appears in fat-loss and body-composition conversations because the mouse data are consistent and the enzyme it targets is a legitimate one. The honest reading is narrower: the compound has never been tested in a person, so any performance or physique framing is extrapolation, not evidence. The most useful role for this page is orientation, explaining why the target is interesting while keeping the empty human column in full view.
Across the Aeternus library, the practical standard is claim matching. A mechanism belongs in mechanism language, a cell or animal model belongs in preclinical language, and a human trial belongs in population-specific human-evidence language. This keeps the entry useful for readers who want orientation without turning biology into personal direction. The strongest interpretation is usually the narrowest accurate one: name the pathway, name the evidence type, name the limits, and leave space for uncertainty where the sources do not answer the question. That standard also protects the reader from a common mistake in this category: assuming that biological relevance automatically creates a usable strategy. It does not. Evidence becomes useful when the claim, source type, population, endpoint, and safety context all line up.
It isn't a peptide, and it isn't approved by any regulator for anything. There's no Investigational New Drug application on the public record, and it isn't on the FDA's list of substances that pharmacies may legally compound. It hasn't been shown to cause fat loss in a human being, because nobody has published a study that looked. When a page tells you what "users report" over eight to sixteen weeks, understand what that means: anecdote, uncontrolled, with no way to separate the compound from the diet, the training, or expectation. And when a page cites the Nature paper as proof the compound works, check the paper. It doesn't test the compound. On anti-doping, 5-Amino-1MQ is not specifically named on the WADA Prohibited List, but a competing athlete should not read that as clearance. Metabolic modulators are a listed category and governing bodies interpret it. Ask yours.
We include 5-Amino-1MQ because it's the most useful kind of teaching case: the science is real and the evidence is thin, at the same time. The enzyme is a legitimate target. The mouse results are consistent across multiple labs. The mechanism makes sense in a way a lot of marketed compounds don't. And none of that adds up to knowing what it does in a person, because nobody has looked. Metabolism is a graveyard for compounds that worked beautifully in rodents. The right posture here isn't dismissal, it's patience. Track it. If a phase 1 trial publishes, the conversation changes. Until then, "promising in mice" is exactly and only what it is.
